Enzyre

Enzyre is a spin-out company from Radboud University Medical Center in Nijmegen, The Netherlands, founded by Waander van Heerde and Guido Maertens. The company aims to develop an ambulant diagnostic technology platform, EnzyPad, that enables hemophilia patients to determine and monitor their coagulation status at home in real-time.

Enzyre's first product, the Hemophilia EnzyCard, utilizes the EnzyPad platform technology to measure up to 16 reactions simultaneously with high sensitivity and specificity using just a small volume of blood. This allows hemophilia patients, who lack sufficient blood-clotting factor VIII activity, to self-test their coagulation status and share the results with their physicians through a cloud-based application and mobile phone app.

The EnzyPad platform offers numerous benefits to patients, including avoiding crisis situations driven by changes in coagulation status, providing peace of mind, empowering patients to optimize their treatment, serving as a quick turnaround tool in clinical settings, reducing GP consultation visits, and offering personalized diagnostic support in a telemedicine setting. This technology has the potential to improve clinical outcomes while decreasing the overall treatment burden and cost for patients and healthcare systems.

In November 2022, Enzyre successfully raised EUR 12 million in a Series A financing round led by new investor Oost NL, with participation from i&i biotech Fund, Demcon Investment as a technology partner, and existing investors Takeda Ventures and Novalis biotech. Part of the funding also came from an Innovation Credit from the Dutch Government. The proceeds will be used to further develop the EnzyPad platform, support clinical trial registrations, establish manufacturing capabilities, and invest in expanding applications in critical care settings.